Neuberger Berman Group LLC reduced its position in shares of Hill-Rom Holdings Inc. (NYSE:HRC) by 7.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,292,264 shares of the medical technology company’s stock after selling 98,888 shares during the period. Neuberger Berman Group LLC’s holdings in Hill-Rom Holdings were worth $80,095,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC boosted its stake in Hill-Rom Holdings by 45.0% in the second quarter. FMR LLC now owns 5,017,977 shares of the medical technology company’s stock worth $253,157,000 after buying an additional 1,557,285 shares during the period. Vanguard Group Inc. boosted its stake in Hill-Rom Holdings by 3.5% in the second quarter. Vanguard Group Inc. now owns 4,356,236 shares of the medical technology company’s stock worth $219,773,000 after buying an additional 149,095 shares during the period. BlackRock Fund Advisors boosted its stake in Hill-Rom Holdings by 12.0% in the second quarter. BlackRock Fund Advisors now owns 2,352,117 shares of the medical technology company’s stock worth $118,664,000 after buying an additional 252,239 shares during the period. Franklin Resources Inc. boosted its stake in Hill-Rom Holdings by 3.7% in the second quarter. Franklin Resources Inc. now owns 1,631,400 shares of the medical technology company’s stock worth $82,304,000 after buying an additional 57,700 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in Hill-Rom Holdings by 3.2% in the third quarter. Fisher Asset Management LLC now owns 1,627,296 shares of the medical technology company’s stock worth $100,860,000 after buying an additional 50,761 shares during the period. Institutional investors and hedge funds own 82.55% of the company’s stock.

Institutional Ownership by Quarter for Hill-Rom Holdings (NYSE:HRC)

Shares of Hill-Rom Holdings Inc. (NYSE:HRC) opened at 54.65 on Tuesday. The company’s 50 day moving average price is $56.90 and its 200 day moving average price is $54.98. The stock has a market capitalization of $3.59 billion, a PE ratio of 29.38 and a beta of 1.20. Hill-Rom Holdings Inc. has a 12 month low of $42.99 and a 12 month high of $63.12.

Hill-Rom Holdings (NYSE:HRC) last posted its quarterly earnings data on Thursday, November 3rd. The medical technology company reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.05. Hill-Rom Holdings had a return on equity of 18.93% and a net margin of 4.67%. The company earned $706 million during the quarter, compared to analysts’ expectations of $701.39 million. During the same period last year, the firm earned $0.89 EPS. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. Equities analysts anticipate that Hill-Rom Holdings Inc. will post $3.78 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 16th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, December 14th. This represents a $0.68 dividend on an annualized basis and a yield of 1.24%. Hill-Rom Holdings’s payout ratio is 36.76%.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this piece can be accessed at http://www.dailypolitical.com/2016/11/29/neuberger-berman-group-llc-has-80095000-stake-in-hill-rom-holdings-inc-hrc.html.

Separately, Zacks Investment Research upgraded Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Wednesday, September 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $62.20.

In other Hill-Rom Holdings news, COO Carlyn D. Solomon sold 40,515 shares of the stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $54.78, for a total transaction of $2,219,411.70. Following the completion of the sale, the chief operating officer now directly owns 22,163 shares of the company’s stock, valued at approximately $1,214,089.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.10% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

5 Day Chart for NYSE:HRC

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings Inc. (NYSE:HRC).

Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.